

KANTAR HEALTH RESEARCH POSTER PRESENTATIONS
ISPOR EUROPE 2018MONDAY
12 NOVEMBER
SESSION I
PRESENTATION08:45 - 13:45 **PSY216****The Relationship between Health-related Quality of Life and Clinical versus Self-reported Body Mass Index**Huynh S¹, Jaffe D², Doane MJ³, Lee LK⁴, Haskell T³¹Kantar Health, New York, NY, USA, ²Kantar Health, Tel Aviv, Israel, ³Kantar Health, Horsham, PA, USA, ⁴Kantar Health, San Mateo, CA, USA

Poster author discussion hour: 12:45 - 13:45

MONDAY
12 NOVEMBER
SESSION II
PRESENTATION15:45 - 19:15 **PMH71****An Assessment of Health Outcomes by Patient Activation Level in the EU5**Carpinella CM¹, Sternbach N², Annunziata K³, Chapnick J⁴, Patel P⁵, McElwee N⁶, McDonald M⁷¹Kantar Health, San Mateo, CA, USA, ²Kantar Health, New York City, NY, USA,³Kantar Health, New York City, NY, USA, ⁴Kantar Health, Horsham, PA, USA,⁵Kantar Health, New York, NY, USA, ⁶inVentivHealth, Manchester, MA, USA,⁷Pfizer Inc, New York, NY, USA

Poster author discussion hour: 18:15 - 19:15

15:45 - 19:15 **PMH72****The Burden of Suicidal Ideation in Europe from the Patient Perspective**Jaffe D¹, Rive B², Denee T³¹Kantar Health, Jerusalem, Israel, ²Janssen EMEA, Paris, France, ³Janssen-Cilag Limited, High Wycombe, UK

Poster author discussion hour: 18:15 - 19:15

15:45 - 19:15 **PMH73****The Burden of Treatment-resistant Depression in Europe from the Patient Perspective**Jaffe D¹, Rive B², Denee T³¹Kantar Health, Jerusalem, Israel, ²Janssen EMEA, Paris, France, ³Janssen-Cilag Limited, High Wycombe, UK

Poster author discussion hour: 18:15 - 19:15

TUESDAY
13 NOVEMBER
SESSION III
PRESENTATION08:45 - 13:30 **PDB11****Chart Review Analysis of Insulin Glargine 300 and Insulin Glargine 100 Use in France, Spain and Germany**Escalada J¹, Bonnet F², Wu J³, Bonnemaire M⁴, Gupta S⁵, Cambron-Mellot MJ⁵, Nicholls C⁶, Müller-Wieland D⁷¹Clinic University of Navarra, Pamplona, Spain, ²Centre Hospitalier Universitaire de Rennes, Rennes, France, ³Sanofi, Bridgewater, NJ, USA, ⁴Sanofi, Paris, France,⁵Kantar Health, New York, NY, USA, ⁶Sanofi, Guildford, SRY, UK, ⁷University

Hospital Aachen, Aachen, Germany

Poster author discussion hour: 12:30 - 13:30

08:45 - 13:30 **PDB128****Comparison of Patient Activation Levels across Various Conditions in the US and EU5**Annunziata K¹, Sternbach N², Carpinella CM³, Chapnick J⁴, Patel P⁵, McDonald M⁶, McElwee N⁷¹Kantar Health, New York City, NY, USA, ²Kantar Health, New York City, NY,USA, ³Kantar Health, San Mateo, CA, USA, ⁴Kantar Health, Horsham, PA,USA, ⁵Kantar Health, New York, NY, USA, ⁶Pfizer Inc, New York, NY, USA,⁷inVentivHealth, Manchester, MA, USA

Poster author discussion hour: 12:30 - 13:30

08:45 - 13:30	PGI48	Patients with Non-alcoholic Steatohepatitis (NASH) Have Worse Related Quality of Life (HRQOL) than Matched Controls: Results from the 2016 EU5 National Health and Wellness Survey (NHWS) Balp M ¹ , Krieger N ² , Przybysz R ² , Way N ³ , Cai J ² , Zappe D ² , <u>Mckenna SJ</u> ⁴ , Wall G ² , Janssens N ¹ , Tapper E ⁵ ¹ Novartis Pharma AG, Basel, Switzerland, ² Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³ Kantar Health, San Mateo, CA, USA, ⁴ Novartis Business Services, Dublin, Ireland, ⁵ University of Michigan, Ann Arbor, MI, USA <i>Poster author discussion hour: 12:30 - 13:30</i>
08:45 - 13:30	PGI51	Patients with Non-alcoholic Steatohepatitis (NASH) Report Higher Economic Burden Than Controls: Results from the EU5 National Health and Wellness Survey (NHWS) Balp M ¹ , Krieger N ² , Przybysz R ² , Way N ³ , Cai J ² , Zappe D ² , <u>Mckenna SJ</u> ⁴ , Wall G ² , Janssens N ¹ , Tapper E ⁵ ¹ Novartis Pharma AG, Basel, Switzerland, ² Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³ Kantar Health, San Mateo, CA, USA, ⁴ Novartis Business Services, Dublin, Ireland, ⁵ University of Michigan, Ann Arbor, MI, USA <i>Poster author discussion hour: 12:30 - 13:30</i>
08:45 - 13:15	PCN11	Global Longitudinal Assessment of Treatment Outcomes in Squamous Cell Carcinoma of the Head and Neck (GLANCE-H&N) Study Gruenwald V ¹ , <u>Chirovsky D</u> ² , Cheung W ³ , Bertolini F ⁴ , Ahn M ⁵ , Yang M ⁶ , de Castro Jr. G ⁷ , Berrocal A ⁸ , Sjoquist K ⁹ , Kuyas H ¹⁰ , Auclair V ¹⁰ , Guillaume X ¹⁰ , Shah R ¹¹ , Harrington K ¹² ¹ Medical School Hannover (MHH), Hannover, Germany, ² Merck and Co. Inc., Kenilworth, NJ, USA, ³ British Columbia Cancer Agency, Vancouver, BC, Canada, ⁴ AOU Policlinico di Modena, Modena, Italy, ⁵ Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁶ Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan, ⁷ ICESP - Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ⁸ Hospital General Universitario de Valencia, Valencia, Spain, ⁹ St George and Sutherland Hospitals, Kogarah NSW, Australia, ¹⁰ Kantar Health, France, France, ¹¹ Merck and Co. Inc., Rahway, NJ, USA, ¹² The Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre, London, UK <i>Poster author discussion hour: 12:15 - 13:15</i>
08:45 - 13:15	PCN67	Budget Impact Model of Subcutaneous Rituximab Compared with Intravenous Rituximab in the Treatment of CD-20 Positive Non-Hodgkin Lymphoma in the Brazilian Private Healthcare System <u>Kashiura D</u> ¹ , Souza PV ² , Sá AB ² , Santos BR ² , Nardi E ¹ , Alves M ² ¹ Evidências - Kantar Health, São Paulo, Brazil, ² F. Hoffmann-La Roche Ltd, São Paulo, Brazil <i>Poster author discussion hour: 12:15 - 13:15</i>
08:45 - 13:15	PCN75	Budget Impact Model of Subcutaneous Trastuzumab Compared with Intravenous Trastuzumab on the Treatment of HER-2 Positive Breast Cancer in the Brazilian Private Healthcare System <u>Kashiura D</u> ¹ , Souza PV ² , Garrido SD ² , Nardi E ¹ , Alves M ² ¹ Evidências - Kantar Health, São Paulo, Brazil, ² F. Hoffmann-La Roche Ltd, São Paulo, Brazil <i>Poster author discussion hour: 12:15 - 13:15</i>
08:45 - 13:15	PCN222	Treatment Patterns and Healthcare Resource Utilization (HCRU) in Advanced Hepatocellular Carcinoma (HCC) in Canada and Europe <u>Jaffe D</u> ¹ , Gill S ² , DeCongelio M ³ , Dubell A ³ , Stetson J ³ , Wisniewski T ⁴ , Thompson GJ ⁵ ¹ Kantar Health, Jerusalem, Israel, ² BC Cancer Agency, Vancouver, BC, Canada, ³ Kantar Health, New York, NY, USA, ⁴ Bristol-Myers Squibb, Princeton, NJ, USA, ⁵ Bristol Myers Squibb, Uxbridge, UK <i>Poster author discussion hour: 12:15 - 13:15</i>
